Management Of Chronic And Acute Pain Takes Center Stage During COVID-19 Pan-demic With Medical Institutions Researching Neuro-stimulation Which Send Electrical Impulses For Relief Of Back And Leg Pain; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Treatments Without Opioid-Addicting Pain Killer Drugs

Posted November 13, 2020

In NASDAQ: AXSM, NYSE: BMY, NYSE: BSX, NYSE: GSK, NYSE: JNJ, NYSE: LLY, NYSE: MDT, NYSE: NVRO, NYSE: NVS, OTCQB: EMED

Cleveland Clinic, National Institutes of Health (NIH), American Society of Anesthesiologists and other medical institutions and professional associations are pursuing non-invasive and non-addictive opioid treatments for chronic and acute pain in a health environment where the COVID-19 pandemic dominates. Prestigious medical facilities have put chronic pain at center stage during the crisis. Treatments being reviewed include minimally-invasive neuro-stimulation using electrical impulses to relieve back and leg pain. Electromedical Technologies, Inc. (OTCQB: EMED) offers Electrotherapy and Bioelectronic treatments through non-invasive devices and without opioid-addicting pain killer drugs.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Management Of Chronic And Acute Pain Takes Center Stage During COVID-19 Pandemic With Medical Institutions Researching Neuro-stimulation Which Send Electrical Impulses For Relief Of Back And Leg Pain; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Treatments Without Opioid-Addicting Pain Killer Drugs

Neuro-Stimulation Is a Treatment Technique For Chronic And Acute Pain

The American Society of Anesthesiologists (ASA) believes that chronic pain management cannot wait for the COVID-19 pandemic to end — it is even more critical during stressful times, it finds. Physicians are focused on in-person medical visits with patients suffering from chronic and acute pain by seeking treatments that reduce visits needed and offer long-lasting relief of pain for six months or more. One technique it cites is neuro-stimulation, a minimally invasive strategy which calls for a device to be implanted under the skin which generates electrical impulses disrupting pain signals.

OVID-19 Seen Adding To Chronic Pain

David Dickerson, M.D. and vice chair of ASA’s Committee On Pain Management, said, “The anxiety and isolation caused by COVID-19 adds to chronic pain, which is further compounded by reduced access to strategies, such as physical therapy, exercise and even visits with the grandkids or other loved ones, that help people management their discomfort.” He said that as patients turn for pain relief through addictive opioid pain killer pharmaceuticals or alcohol, physician anesthesiologists who specialize in pain medicine have become creative to offering relief to their patients.

Electromedical Technologies, Inc. (OTCQB: EMED) Offers Chronic And Acute Pain Relief Through its Devices: the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod

Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. These are non-invasive devices which avoid side-effects such as opioid addiction. They deliver to sufferers of chronic and acute pain relief with electrotherapy and bioelectronic offered by these devices. Management Of Chronic And Acute Pain Takes Center Stage During COVID-19 Pandemic With Medical Institutions Researching Neuro-stimulation Which Send Electrical Impulses For Relief Of Back And Leg Pain; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Treatments Without Opioid-Addicting Pain Killer Drugs.

The Future Of Medicine

Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in the field of addressing acute and chronic pain and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals, is only made worse by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical physician visits, postpone surgical treatments and limit out-of-home mobility.

StreetInsider.com says electrotherapy and bioelectronic treatments can be helpful in treating chronic and acute pain without addictive drugs. It terms the Electromedical Technologies, Inc. (OTCQB: EMED) devices as in the forefront of the future of medicine. Matthew Wolfson, founder and CEO of EMED, has pursued collaboration with universities and schools on chronic pain research and certification training that offers a ‘Bioelectronics Therapist and Master Device Technician.’ The goal is to educate students and physicians on the techniques and benefits that use drug free application for treatment of chronic, acute and intractable pain.

The National Institutes Of Health (NIH) has raised the stakes on chronic pain and possible treatment that leads to opioid addiction through pain killer pharmaceuticals. NIH awarded its ‘Pain Research Center’ additional funding through its Director’s Challenge Innovative Award program in 2020 as it seeks to focus research on chronic pain and its treatments in part to discover new therapies that are not opioid-addictive.

The NIH said, “Chronic pain affects millions of people, lacks effective treatments and and is a primary driver of opioid misuse disorders.” Cleveland Clinic, a prestigious medical institution, is offering multi-disciplinary relief through its Cleveland Clinic-Martin Health pain management center in Florida. Management Of Chronic And Acute Pain Takes Center Stage During COVID-19 Pandemic With Medical Institutions Researching Neuro-stimulation Which Send Electrical Impulses For Relief Of Back And Leg Pain; Electromedical Technologies, Inc. (OTCQB: EMED) Offers Electrotherapy And Bioelectronic Treatments Without Opioid-Addicting Pain Killer Drugs.

Science Daily informs that the University of Arizona Health Sciences is researching chronic pain related to COVID-19 and why some who have the disease suffer no pain. The reason, they say, is because early on the pain from the disease is suppressed by another protein from within the body contracted from SARS. It can silence the body’s pain signaling pathways. If correct, that assumption is key to exploring non-addictive therapeutics to relieve chronic pain, the school said.

Pain Treatment Market Seen Reaching $151.7 Billion Globally By 2030

A new research study by The Centers For Disease Control And Prevention (CDC) finds that greater than 20% of American adults suffer from chronic pain and high-impact chronic pain, sometimes resulting in opioid dependence. The COVID-19 pandemic, a recent study by Prescient & Strategic Intelligence reports, only exacerbates these numbers and helps drive the chronic pain treatment market globally by a 6.5% CAGR rate to $151.7 Billion by 2030 from $77.8 Billion in 2019.

EMED Plans To Study The Effects Of Electro-Modulation On The Human Body

Electromedical Technologies, Inc. (OTCQB: EMED) offers a growing line of devices that deliver electrotherapy treatment for chronic and acute pain. Next year, the Company anticipates bringing to market its WellnessPro® Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

Nitin Harlalka

Nitin Harlalka is a Stock Market Press contributor who has covered financial market for close a decade. With a graduate degree in Economics, Nitin has been a freelance stock market and business journalist for a range of publications. Most recently, he has covered emerging industries such as cannabis and blockchain.